8-K
filed September 3, 2026, 8:53 AM ET
ticker APGE
CIK 0001974640
M&A
confidence high
sentiment neutral
materiality 1.00
Apogee completes $10.9B acquisition by AbbVie; shareholders get $135.11/share
Apogee Therapeutics, Inc.
- Merger completed Sept 3, 2026; each share converted to $135.11 cash, total equity value ~$10.9B.
- Company to delist from Nasdaq; trading suspended Sept 4, 2026, Form 25 to be filed.
- All directors resigned; new directors from Merger Sub appointed; execs stepped down.
- Parachute payment agreements with named execs, capped at $12.5M aggregate for 280G gross-ups.
- 2023 Equity Incentive Plan and ESPP terminated effective at close.
Featured in Daily 8-K Digest
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lisa Bollinger resigned as Director at Apogee Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
all of the Company’s directors (Michael Henderson, M.D., Mark C. McKenna, Lisa Bollinger, M.D., Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak and Nimish Shah) voluntarily resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mark C. McKenna resigned as Director at Apogee Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
all of the Company’s directors (Michael Henderson, M.D., Mark C. McKenna, Lisa Bollinger, M.D., Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak and Nimish Shah) voluntarily resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tomas Kiselak resigned as Director at Apogee Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
all of the Company’s directors (Michael Henderson, M.D., Mark C. McKenna, Lisa Bollinger, M.D., Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak and Nimish Shah) voluntarily resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jennifer Fox resigned as Director at Apogee Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
all of the Company’s directors (Michael Henderson, M.D., Mark C. McKenna, Lisa Bollinger, M.D., Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak and Nimish Shah) voluntarily resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Henderson resigned as Director at Apogee Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
all of the Company’s directors (Michael Henderson, M.D., Mark C. McKenna, Lisa Bollinger, M.D., Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak and Nimish Shah) voluntarily resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
William (BJ) Jones resigned as Director at Apogee Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
all of the Company’s directors (Michael Henderson, M.D., Mark C. McKenna, Lisa Bollinger, M.D., Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak and Nimish Shah) voluntarily resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nimish Shah resigned as Director at Apogee Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
all of the Company’s directors (Michael Henderson, M.D., Mark C. McKenna, Lisa Bollinger, M.D., Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak and Nimish Shah) voluntarily resigned from the Company’s board of directors
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.